Across TCGA pan-cancer cohorts, BTBD8 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BTBD8 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher BTBD8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BTBD8 expression acts as an unfavorable survival marker.
BLCA, HNSC, and UCEC are the cancer types where BTBD8 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.